The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes .
Because outcome data at this dose are lacking , HCTZ is an inappropriate first-line drug for the treatment of hypertension
OBJECTIVES The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide ( HCTZ ) by ambulatory blood pressure ( BP ) monitoring .
BACKGROUND HCTZ is the most commonly prescribed antihypertensive drug worldwide .
More than 97 % of all HCTZ prescriptions are for 12.5 to 25 mg per day .
The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined .
Candesartan and hydrochlorothiazide in isolated systolic hypertension
Aim : We investigated the efficacy and safety of daily c and esartan 8/16 mg and hydrochlorothiazide 12.5 mg as monotherapy and in combination in older patients with systolic hypertension . Methods : The study used a double-blind r and omized placebo-controlled crossover design . Treatment phases were of 6 weeks duration . For inclusion , patients were aged 55 - 84 years with sitting systolic blood pressure ( SBP ) 160 - 210 mmHg and diastolic blood pressure ( DBP ) < 95 mmHg . Nineteen patients ( 11 male , eight female , median age 68 years ) completed the study . Major findings : Compared with the placebo phase , clinic and ambulatory SBP was significantly reduced with both dose-adjusted c and esartan and fixed-dose hydrochlorothiazide as monotherapy , the effect of c and esartan being greater than that of hydrochlorothiazide . In combination , the effects of the two drugs were additive . Both drugs were well tolerated either as monotherapy or in combination . Conclusion : Both c and esartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination . C and esartan was more effective than hydrochlorothiazide , although it is possible that dose adjustment only of c and esartan could have enhanced its relative effectiveness
The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes .
Because outcome data at this dose are lacking , HCTZ is an inappropriate first-line drug for the treatment of hypertension
OBJECTIVES The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide ( HCTZ ) by ambulatory blood pressure ( BP ) monitoring .
BACKGROUND HCTZ is the most commonly prescribed antihypertensive drug worldwide .
More than 97 % of all HCTZ prescriptions are for 12.5 to 25 mg per day .
The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined .